|Table of Contents|

Research progress of exosomal PD-L1 in tumor immunotherapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 01
Page:
178-181
Research Field:
Publishing date:

Info

Title:
Research progress of exosomal PD-L1 in tumor immunotherapy
Author(s):
YAN Min1; YU Sijia1; DENG Shishan2; LI Dezhi3
1.Department of Oncology,Nanchong City Central Hospital Affiliated to North Sichuan Medical College,Sichuan Nanchong 637000,China;2.Basic Medical School，Basic Medical College of North Sichuan Medical College,Sichuan Nanchong 637000,China；3.Department of
Keywords:
exosomes; programmed cell death protein-ligand-1; neoplasms; immunotherapy
PACS:
R730.51
DOI:
10.3969/j.issn.1672-4992.2022.01.040
Abstract:
Currently,major progress has been made in tumor immunotherapy,the new immunotherapy represented by programmed cell death protein-1(PD-1)/programmed cell death protein-ligand 1(PD-L1)inhibitors is in full momentum of clinical application.However,in the application of PD-1/PD-L1 inhibitors.There are significant differences in efficacy between different patients and different tumor types.The latest study found that exosomal PD-L1 can explain this difference in efficacy.The main mechanism is that exosomal PD-L1 can replace cell PD-L1 and inhibit T cell activation.Meanwhile,it can also transfer functional PD-L1 to other cells to generate immune resistance or tolerance,affecting the outcome of PD-1/PD-L1 inhibitors treatment.And the relationship between exosomal PD-L1 and tumor immunotherapy is briefly introduced in this paper.

References:

[1]JIANG Y,CHEN M,NIE H,et al.PD-1 and PD-L1 in cancer immunotherapy:clinical implications and future considerations［J］.Hum Vaccin Immunother,2019,15(5):1111-1122.
[2]KIM SH,BIANCO NR,SHUFESKY WJ,et al.MHC class Ⅱ+exosomes in plasma suppress inflammation in an antigen-specific and Fas ligand/Fas-dependent manner［J］.J Immunol,2007,179(4):2235-2241.
[3]DAI J,SU Y,ZHONG S,et al.Exosomes:key players in cancer and potential therapeutic strategy［J］.Signal Transduct Target Ther,2020,5(1):145.
[4]SHENOY GN,LOYALL J,MAGUIRE O,et al.Exosomes associated with human ovarian tumors harbor a reversible checkpoint of T-cell responses［J］.Cancer Immunol Res,2018,6(2):236-247.
[5]OLEJARZ W,DOMINIAK A,ZOLNIERZAK A,et al.Tumor-derived exosomes in immunosuppression and immunotherapy［J］.J Immunol Res,2020,2020:6272498.
[6]CHEN G,HUANG AC,ZHANG W,et al.Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response［J］.Nature,2018,560(7718):382-386.
[7]KAMIMURA N,WOLF AM,LWAI Y.Development of cancer immunotherapy targeting the PD-1 pathway［J］.J Nippon Med Sch,2019,86(1):10-14.
[8]FRANCISCO LM,SALINAS VH,BROWN KE,et al.PD-L1 regulates the development,maintenance,and function of induced regulatory T cells［J］.J Exp Med,2009,206(13):3015-3029.
[9]MARTIN AM,NIRSCHL TR,NIRSCHL CJ,et al.Paucity of PD-L1 expression in prostate cancer:innate and adaptive immune resistance［J］.Prostate Cancer Prostatic Dis,2015,18(4):325-332.
[10]POGGIO M,HU T,PAI CC,et al.Suppression ofexosomal PD-L1 induces systemic anti-tumor immunity and memory［J］.Cell,2019,177(2):414-427.
[11]YANG Y,LI CW,CHAN LC,et al.Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth［J］.Cell Res,2018,28(8):862-864.
[12]RICKLEFS FL,ALAYO Q,KRENZLIN H,et al.Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles［J］.Sci Adv,2018,4(3):r2766.
[13]LI C,LI C,ZHI C,et al.Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients［J］.J Transl Med,2019,17(1):355.
[14]THEODORAKI MN,YERNENI SS,HOFFMANN TK,et al.Clinical significance of PD-L1(＋)exosomes in plasma of head and neck cancer patients［J］.Clin Cancer Res,2018,24(4):896-905.
[15]DEL RM,MARCONCINI R,PASQUINI G,et al.PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC［J］.Br J Cancer,2018,118(6):820-824.
[16]FAN Y,CHE X,QU J,et al.Exosomal PD-L1 retains immunosuppressive activity and is associated with gastric cancer prognosis［J］.Ann Surg Oncol,2019,26(11):3745-3755.
[17]KIM DH,KIM H,CHOI YJ,et al.Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer［J］.Exp Mol Med,2019,51(8):1-13.
[18]JANSE VAN RENSBERG HJ,AZAD T,LING M,et al.The hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1［J］.Cancer Res，2018,78:1457-1470.
[19]TANG Y,ZHANG P,WANG Y,et al.The biogenesis,biology,and clinical significance of exosomal PD-L1 in cancer［J］.Front Immunol,2020,11:604.
[20]ZHANG M,FAN Y,CHE X,et al.5-FU-induced upregulation of exosomal PD-L1 causes immunosuppression in advanced gastric cancer patients［J］.Front Oncol,2020,10:492.
[21]THEODORAKI MN,YERNENI S,GOODING WE,et al.Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab,ipilimumab,and IMRT［J］.Oncoimmunology,2019,8(7):1593805.
[22]SABARI JK,LEONARDI GC,SHU CA,et al.PD-L1 expression,tumor mutational burden,and response to immunotherapy in patients with MET exon 14 altered lung cancers［J］.Ann Oncol,2018,29(10):2085-2091.
[23]MORRISSEY SM,YAN J.Exosomal PD-L1:Roles intumor progression and immunotherapy［J］.Trends Cancer,2020,6(7):550-558.
[24]江白玲.肠道菌群和外泌体PD-L1表达与抗PD-1单抗治疗晚期肝癌疗效的关系［D］.南昌：南昌大学,2020. JIANG BL.Relationship between gut microbiome and exosomal PD-L1 expression and the efficacy of PD-1 blockade therapy in advanced hepotacellular carcinama［D］.Nanchang：Nanchang University,2020.
[25]FEHRENBACHER L,SPIRA A,BALLINGER M,et al.Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer(POPLAR):a multicentre,open-label,phase 2 randomised controlled trial［J］.Lancet,2016,387(10030):1837-1846.
[26]MA J,LI J,QIAN M,et al.PD-L1 expression and the prognostic significance in gastric cancer:a retrospective comparison of three PD-L1 antibody clones(SP142,28-8 and E1L3N)［J］.Diagn Pathol,2018,13(1):91.
[27]NG KW,ATTIG J,YOUNNG GR,et al.Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist［J］.Elife,2019,8:e50256.
[28]LUX A,KAHLERT C,GRUTZMANN R,et al.c-Met and PD-L1 oncirculating exosomes as diagnostic and prognostic markers for pancreatic cancer［J］.Int J Mol Sci,2019,20(13):3305.
[29]ZHANG C,FAN Y,CHE X,et al.Anti-PD-1 therapy response predicted by the combination of exosomal PD-L1 and CD28［J］.Front Oncol,2020,10:760.
[30]CORDONNIER M,NARDIN C,CHANTELOUP G,et al.Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients［J］.J Extracell Vesicles,2020,9(1):1710899.
[31]董召.晚期恶性肿瘤患者血浆外泌体PD-L1表达与肿瘤组织中PD-L1表达相关性的研究［D］.沈阳：中国医科大学,2019,02(2):36. DONG Z,The correlation between the expression of PD-L1 in exosome isolated from plasma and the expression of PD-L1in tumor tissues in patients with advanced malignant tumors［D］.Shenyang:China Medical University,2019,02(2):36.
[32]YU X,SHA L,DONG L,et al.Recent advances in bio-sensing methods for the detection of tumor exosomes［J］.Crit Rev Anal Chem,2020,06(8):1-19.
[33]HUANG M,YANG J,WANG T,et al.Homogeneous,low-volume,efficient,and sensitive quantitation of circulating exosomal PD-L1 for cancer diagnosis and immunotherapy response prediction［J］.Angew Chem Int Ed Engl,2020,59(12):4800-4805.
[34]LIU C,ZENG X,AN Z,et al.Sensitivedetection of exosomal proteins via a compact surface plasmon resonance biosensor for cancer diagnosis［J］.ACS Sens,2018,3(8):1471-1479.
[35]MATSUMOTO A,TAKAHASHI Y,NISHIKAWA M,et al.Role of phosphatidylserine-derived negative surface charges in the recognition and uptake of intravenously injected B16BL6-derived exosomes by macrophages［J］.J Pharm Sci,2017,106(1):168-175.
[36]WANG H,YAO H,LI C,et al.HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity［J］.Nat Chem Biol,2019,15(1):42-50.

Memo

Memo:
四川省教育厅创新团队项目（编号：17TD0016）；四川省南充市科技与知识产权局创新驱动发展专项（编号：16CXQD0042）
Last Update: 2021-12-02